Histone H1 inhibitors( Neurocrine Biosciences, Inc.)(Histone H1 inhibitors( Neurocrine Biosciences, Inc.)) - 药物靶点：组蛋白H1_在研适应症：睡眠异常_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

组蛋白H1

作用机制

组蛋白H1抑制剂

治疗领域

神经系统疾病

在研适应症

睡眠异常

非在研适应症-

原研机构

Neurocrine Biosciences, Inc.

在研机构

Neurocrine Biosciences, Inc.

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 Histone H1 inhibitors( Neurocrine Biosciences, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Histone H1 inhibitors( Neurocrine Biosciences, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Histone H1 inhibitors( Neurocrine Biosciences, Inc.) 相关的专利（医药）

登录后查看更多信息

1

项与 Histone H1 inhibitors( Neurocrine Biosciences, Inc.) 相关的文献（医药）

Communications Biology

Cpt1a Drives primed-to-naïve pluripotency transition through lipid remodeling

Article

作者: Huang, Xingnan ; Qin, Yue ; Pei, Duanqing ; Li, Pengli ; Ma, Zhaoyi ; Wang, Qiannan ; Zhao, Chengchen ; Liang, Zechuan ; Wang, Xiaomin ; Zhai, Ziwei ; Kuang, Junqi ; Fan, Yixin ; Li, Wei ; Huang, Tao ; Wang, Bo ; Ming, Jin ; Fu, Yu

Metabolism has been implicated in cell fate determination, particularly through epigenetic modifications. Similarly, lipid remodeling also plays a role in regulating cell fate. Here, we present comprehensive lipidomics analysis during BMP4-driven primed to naive pluripotency transition or BiPNT and demonstrate that lipid remodeling plays an essential role. We further identify Cpt1a as a rate-limiting factor in BiPNT, driving lipid remodeling and metabolic reprogramming while simultaneously increasing intracellular acetyl-CoA levels and enhancing H3K27ac at chromatin open sites. Perturbation of BiPNT by histone acetylation inhibitors suppresses lipid remodeling and pluripotency transition. Together, our study suggests that lipid remodeling promotes pluripotency transitions and further regulates cell fate decisions, implicating Cpt1a as a critical regulator between primed-naive cell fate control.

100 项与 Histone H1 inhibitors( Neurocrine Biosciences, Inc.) 相关的药物交易

登录后查看更多信息